HPHeather L. Platt

Heather L. Platt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heather L. Platt has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8

    by Paul T Scott, Jayani Pathirana, Akira Kato, Richard Tytus, Carlos M Perez, Nigel Leslie Gilchrist, Hidemi Kanou, Kwang Ha Yoo, Grzegorz Kania, Michael Nissen, et al.

    Background: Pneumococcal disease (PD) is a major cause of hospitalization and mortality in adults. Individuals with certain chronic illnesses are at increased risk for PD. Methods: This phase 3, randomized, double-blind, active comparator-controlled trial (NCT05696080) evaluated the safety and immunogenicity of 21-valent pneumococcal conjugate vaccine (V116) in adults 18–64 years of age with ≥1 condition associated with increased risk of PD (diabetes mellitus or kidney, heart, liver, or lung disease). Participants were given a single dose of either V116 followed by placebo or 15-valent pneumococcal conjugate vaccine (PCV15), followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later. Immune responses were evaluated by opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) at 30 days postvaccination (day 30 for V116; week 12 for PCV15 + PPSV23). Proportions of participants who experienced adverse events (AEs) within 5 days postvaccination and serious AEs (SAEs) or deaths during the study were assessed. Results: V116 was immunogenic for all 21 serotypes contained in the vaccine. OPA GMTs and IgG GMCs following V116 vaccination were comparable to PCV15 + PPSV23 for the 13 serotypes common between vaccine groups. For the eight serotypes unique to V116, immune responses were higher following V116 compared with PCV15 + PPSV23. V116 was well tolerated compared with PCV15 + PPSV23; no vaccine-related SAEs or deaths were reported. Conclusions: V116 elicits robust immune responses and is well tolerated in adults 18–64 years of age with conditions associated with an increased risk of PD.


  • Open Access

    Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116

    by Jianing Li, Heather L. Platt, Wenyu Hu, Weifeng Xu, Timothy J. Chapman, Katrina M. Nolan, Jonathan Hartzel, Ulrike K. Buchwald

    Background Pneumococcal conjugate vaccines (PCVs) are designed to induce serotype-specific antibodies; however, antibodies raised against pneumococcal polysaccharides in the vaccine can also cross-react to other serotypes based on structural similarities. Cross-reactivity has been demonstrated for some licensed PCVs and is a worthy consideration to broaden protection against pneumococcal disease. This secondary analysis examined cross-reactive immune responses within serogroups 6 and 15 following vaccination with V116, an adult-specific PCV. Methods Antibody levels were assessed across five phase 3 clinical studies at baseline and 30 days following vaccination. Results V116 elicits functional antibodies to vaccine serotypes 6A and 15C that result in cross-reactive antibodies to serotypes 6C and 15B, respectively, as assessed by opsonophagocytic activity responses from pre- to post-vaccination and IgG geometric mean concentrations. Conclusions V116-induced antibodies demonstrate cross-reactivity to serotypes 6C and 15B, suggesting protective immune responses may be raised against these non-vaccine serotypes.


  • Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies

    by Weifeng Xu, Joseph Antonello, Jennifer Nguyen, Chuying Ma, Ya-Wen Cheng, Kasia Marullo, Katrina Nolan, Ulrike K Buchwald, Heather L Platt, Marie Bonhomme, et al.

    Background: The opsonophagocytic assay (OPA) is the gold standard for measuring functional antibody responses to bacterial vaccines. However, antibody-independent bactericidal activities, such as those by antibiotics, could contribute to the killing and thus inflate the measured antibody titer. Because of this, an intrinsic killing (IK) assay is currently required to screen and exclude samples with antibody-independent bactericidal activities. Methods: Here, we utilized multiple phase 3 studies of V116 (Capvaxive), as well as in vitro antibiotic spiked samples with known OPA titers, to gain in-depth insights regarding the impact and necessity of the IK screening testing. Results: Our results show that even at the highest clinically relevant blood concentration, an antibiotic such as amoxicillin only contributes to a titer of about 50 in the antibody-depleted serum sample. Consistent with this, IK positivity in V116 phase 3 studies only showed higher geometric mean titers (GMTs) in the pre-vaccinated, baseline population when the GMTs are lower than 320. After vaccination, no significant differences in OPA titers were observed between IK-positive and IK-negative samples. This, combined with the low rate of IK positivity in healthy adults of V116 clinical studies (≤2% in each study), demonstrated that including IK-positive samples did not alter the relevant clinical assessments of opsonophagocytic activity. Conclusions: Thus, eliminating the IK assay as a requirement for OPA testing could be considered in healthy adult populations where antibiotic use is well-regulated.

  • Open Access

    Correction: Feemster et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. Vaccines 2024, 12, 974

    by Kristen Feemster, William P. Hausdorff, Natalie Banniettis, Heather Platt, Priscilla Velentgas, Alejandra Esteves-Jaramillo, Robert L. Burton, Moon H. Nahm, Ulrike K. Buchwald

    The authors would like to make the following corrections to this published paper

  • Anticipated impact of novel adult-specific pneumococcal conjugate vaccine

    by R. Joshi, H.T. Ayele, K.D. Johnson, P. Velentgas, H. Platt, P. Saddier


  • Open Access

    A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)

    by Veronika Jotterand, Vinita Jagannath, Andrea Accini Diaz, Juan Diego Velez, Arna Letica, Silvia Narejos Perez, Rebecca Clark, Yoseph Caraco, Olaf Degen, Kyung-Hwa Park, et al.

    Background: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) designed for adults. It contains the most prevalent serotypes associated with invasive pneumococcal disease (IPD) in adults in regions with established pediatric vaccination programs. This Phase 3 study compared the safety, tolerability, and immunogenicity of V116 with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults ≥50 years of age. Methods: In this randomized, active comparator-controlled, parallel-group, multisite, double-blind study, participants were randomized 1:1 to receive a single dose of V116 or PPSV23 (NCT05569954). Primary immunogenicity outcomes assessed the opsonophagocytic activity (OPA) responses for (i) non-inferiority for 12 serotypes common to V116 and PPSV23 based on V116/PPSV23 geometric mean titers (GMTs) at Day 30, and (ii) superiority for nine serotypes unique to V116 using V116/PPSV23 GMTs and the proportions of participants with a ≥4-fold rise in OPA responses from baseline to 30 days post-vaccination. The primary safety outcome was evaluated as the proportion of participants with solicited injection-site and systemic adverse events through Day 5 post-vaccination, and vaccine-related serious adverse events up to 6 months post-vaccination. Findings: V116 was non-inferior to PPSV23 for all 12 common serotypes, superior to PPSV23 for all nine unique serotypes based on V116/PPSV23 GMTs, and superior to PPSV23 for eight of the nine serotypes unique to V116, based on the proportion of participants with a ≥4-fold rise in OPA responses (except for serotype 15C). The safety profile of V116 was comparable to that of PPSV23. Interpretation: In regions with established vaccination programs, V116 could broaden the serotype coverage for residual pneumococcal disease in adults.


  • Open Access

    Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development

    by Kristen Feemster, William P. Hausdorff, Natalie Banniettis, Heather Platt, Priscilla Velentgas, Alejandra Esteves-Jaramillo, Robert L. Burton, Moon H. Nahm, Ulrike K. Buchwald

    Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide. Pneumococcal vaccine composition is based on the polysaccharide capsule of Streptococcus pneumoniae, which is one of the most important identified contributors to the pathogen’s virulence. Similarities in the structural composition of polysaccharides included in licensed pneumococcal vaccines may result in cross-reactivity of immune response against closely related serotypes, including serotypes not included in the vaccine. Therefore, it is important to understand whether cross-reactive antibodies offer clinical protection against pneumococcal disease. This review explores available evidence of cross-reactivity and cross-protection associated with pneumococcal vaccines, the challenges associated with the assessment of cross-reactivity and cross-protection, and implications for vaccine design and development.


  • Open Access

    A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

    by Paul Scott, Miwa Haranaka, Jung Hyun Choi, Helen Stacey, Marc Dionne, David Greenberg, Carlos G Grijalva, Walter A Orenstein, Doreen Fernsler, Nancy Gallagher, et al.

    Background: Pneumococcal diseases cause considerable morbidity and mortality in adults. V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed to protect adults from pneumococcal serotypes responsible for the majority of residual pneumococcal diseases. This phase 3 study evaluated safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine–experienced adults aged ≥50 years. Methods: A total of 717 adults were enrolled to receive a single dose of pneumococcal vaccine as follows: cohort 1 (n = 350) previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23) and were randomized 2:1 to receive V116 or PCV15, respectively; cohort 2 (n = 261) previously received PCV13 and were randomized 2:1 to receive V116 or PPSV23, respectively; cohort 3 (n = 106) previously received PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15 and all received open-label V116. Immunogenicity was evaluated 30 days postvaccination using opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) for all V116 serotypes. Safety was evaluated as the proportion of participants with adverse events (AEs). Results: V116 was immunogenic across all 3 cohorts as assessed by serotype-specific OPA GMTs and IgG GMCs postvaccination for all 21 serotypes. V116 elicited comparable immune responses to serotypes shared with PCV15 (cohort 1) or PPSV23 (cohort 2), and higher immune responses to serotypes unique to V116. The proportions of participants with solicited AEs were generally comparable across cohorts. Conclusions: V116 is well tolerated with a safety profile comparable to currently licensed pneumococcal vaccines and generates IgG and functional immune responses to all V116 serotypes, regardless of prior pneumococcal vaccine received. Clinical Trials Registration: NCT05420961; EudraCT 2021-006679-41.